MedTrace Logo

The Oscillation for Acute Respiratory Distress Syndrome (ARDS) Treated Early (OSCILLATE) Trial

NCT01506401 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 548

Last updated 2015-08-06

No results posted yet for this study

Summary

What is the effect of early high frequency oscillation (HFO) versus a lung-protective conventional ventilation (CV) strategy (using HFO only as rescue therapy), on all-cause hospital mortality among patients with severe early acute respiratory distress syndrome (ARDS)?

Conditions

  • Acute Respiratory Distress Syndrome (ARDS)

Interventions

DEVICE

SensorMedics 3100B High Frequency Oscillatory Ventilator

High Frequency Oscillation

PROCEDURE

Lung Protective Ventilation

Tidal Volume 6ml/kg; plateau pressure \< or = 35cmH20; Prescribed PEEP/FiO2 chart

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV

  • McMaster University

    collaborator OTHER

  • University of Toronto

    collaborator OTHER

  • Canadian Critical Care Trials Group

    lead OTHER

Principal Investigators

  • Niall D Ferguson, MD, MSc · University of Toronto

  • Maureen O Meade, MD, MSc · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United States
  • Canada
  • Chile
  • India
  • Saudi Arabia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01506401 on ClinicalTrials.gov